Trial Profile
Multicenter Randomized Placebo-Controlled Investigator Initiated Clinical Trial in Active Rheumatoid Arthritis to evaluate the impact of antiCCP status on ACR response in the combinational therapy of Rituximab and Leflunomide
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2018
Price :
$35
*
At a glance
- Drugs Leflunomide (Primary) ; Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 13 Jul 2018 New trial record